Landmark Kaplan-Meier PFS curves for PET2-negative patients. These curves exclude the 9 patients who were PET3 positive/progressed at time of PET3 or progressed shortly after PET3 assessment using the combined median posttherapy TARC (502.86 pg/mL) and IL-10 (0.2703 pg/mL) levels for these patients as cutoffs, respectively (log-rank test, P = .03). CT, computed tomography.